Carisma Therapeutics, Inc.
CARM · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $20 | $15 | $10 | $27 |
| % Growth | 31.6% | 51.7% | -63% | – |
| Cost of Goods Sold | $60 | $74 | $0 | $0 |
| Gross Profit | -$40 | -$59 | $10 | $26 |
| % Margin | -204% | -396.8% | 100% | 99.7% |
| R&D Expenses | $60 | $74 | $57 | $25 |
| G&A Expenses | $20 | $30 | $9 | $0 |
| SG&A Expenses | $20 | $30 | $9 | $29 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | -$58 | -$74 | $0 | $0 |
| Operating Expenses | $22 | $30 | $66 | $55 |
| Operating Income | -$62 | -$89 | -$56 | -$28 |
| % Margin | -316.7% | -594.8% | -571.1% | -106.1% |
| Other Income/Exp. Net | $2 | $2 | -$5 | $20 |
| Pre-Tax Income | -$60 | -$87 | -$61 | -$9 |
| Tax Expense | $0 | $0 | $0 | -$8 |
| Net Income | -$60 | -$87 | -$61 | -$0 |
| % Margin | -308.1% | -582.3% | -622.6% | -1.3% |
| EPS | -1.46 | -2.59 | -1.52 | -1.01 |
| % Growth | 43.6% | -70.4% | -50.5% | – |
| EPS Diluted | -1.46 | -2.59 | -1.52 | -1.01 |
| Weighted Avg Shares Out | 41 | 34 | 40 | 9 |
| Weighted Avg Shares Out Dil | 41 | 34 | 40 | 9 |
| Supplemental Information | – | – | – | – |
| Interest Income | $2 | $2 | $0 | $0 |
| Interest Expense | $0 | $0 | $3 | $0 |
| Depreciation & Amortization | $3 | $3 | $2 | $0 |
| EBITDA | -$57 | -$86 | -$56 | -$9 |
| % Margin | -289.5% | -575.7% | -571.4% | -32.1% |